KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Vir Biotechnology (VIR) Receivables - Net (2020 - 2022)

Vir Biotechnology's Receivables - Net history spans 3 years, with the latest figure at $7.0 million for Q2 2022.

  • For Q2 2022, Receivables - Net changed N/A year-over-year to $7.0 million; the TTM value through Jun 2022 reached $7.0 million, changed N/A, while the annual FY2021 figure was $773.1 million, N/A changed from the prior year.
  • Receivables - Net for Q2 2022 was $7.0 million at Vir Biotechnology, down from $1.2 billion in the prior quarter.
  • Across five years, Receivables - Net topped out at $1.2 billion in Q1 2022 and bottomed at $3.8 million in Q2 2020.
  • The 3-year median for Receivables - Net is $102.8 million (2021), against an average of $368.8 million.
  • The largest YoY upside for Receivables - Net was 987.25% in 2022 against a maximum downside of 987.25% in 2022.
  • A 3-year view of Receivables - Net shows it stood at $3.8 million in 2020, then soared by 20244.18% to $773.1 million in 2021, then crashed by 99.09% to $7.0 million in 2022.
  • Per Business Quant, the three most recent readings for VIR's Receivables - Net are $7.0 million (Q2 2022), $1.2 billion (Q1 2022), and $773.1 million (Q4 2021).